Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090684 · ClinicalTrials.gov registry record · Phase 1
Ciprofloxacin/Celecoxib Combination in Patients With ALS
A Phase 1 study, sponsored by NeuroSense Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04090684 is a Phase 1 study that has completed, run by NeuroSense Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT04090684, a Phase 1 study, has completed, sponsored by NeuroSense Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity).
Interventions
- DRUG Fixed dose combination Ciprofloxacin/Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04090684
The ClinicalTrials.gov registry entry for NCT04090684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroSense Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fixed dose combination Ciprofloxacin/Celecoxib is the first listed.
NCT04090684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04090684 about?
NCT04090684 is a clinical study titled "Ciprofloxacin/Celecoxib Combination in Patients With ALS". This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity).
What is the current status of trial NCT04090684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-12-09. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT04090684?
The interventions under investigation include: Fixed dose combination Ciprofloxacin/Celecoxib (DRUG).
Who is sponsoring clinical trial NCT04090684?
This trial is sponsored by NeuroSense Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.